Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced positive results from preclinical studies of QGC001, its lead monotherapy candidate for the treatment of hypertension, demonstrating the absence of genotoxicity in animals and no risk of phototoxicity.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2017/03/QGC_PR_QGC001-Genotox_20170314_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
